The Consortium
The MitoTarget consortium has extensive expertise in neurodegenerative diseases
The information provided in this web site is intended to educate the reader about certain medical conditions and certain possible treatments. It is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. If you believe you, suffer from the conditions described herein, please see your health care provider. Do not attempt to treat yourself or anyone else without proper medical supervision.
Read the Full Disclaimer
Institutions & Investors
Latest News
Actelion joins forces with Trophos to further advance olesoxime to the market once results of the MitoTarget clinical study are known.
Actelion obtains option to acquire privately-held Trophos Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be furth
Trophos completes patients enrolment in ALS trial
Trophos completes patient enrolment in pivotal phase 3 efficacy study of olesoxime in Amyotrophic Lateral Sclerosis (Lou Gehrig's disease) Topline results of the study are expected 4th quarter 20
MitoTarget Launches New Online Resource for Physicians and Sufferers from Rare Illness ALS (also known as Lou Gehrig’s disease)
Marseille, France, March 8, 2010 - Trophos, the pharmaceutical company specialising in therapies for orphan diseases including ALS, announces today, on behalf of the MitoTarget consortium, the lau
